Here is some news:
------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Contact:
Dr. Jeff Garwin
BioModa Inc.
Phone: 888-848-8594
Email: info@biomoda.com
Web Site: biomoda.com
Medical / Business News
FOREIGN PATENTS ISSUE ON LUNG CANCER TECHNOLOGY
[Albuquerque, New Mexico 10/2/98]. BioModa Inc. announced today that
patents covering its worldwide, exclusively licensed technology have
issued in Australia, Korea, and the Russian Federation.
Claims were approved that protect BioModa's exclusive right to use TCPP
to screen for lung cancer in sputum samples. Other approved claims
protect BioModa's exclusive right to use radioactive Copper bound to
TCPP for imaging lung cancer in patients, as well as for treating lung
cancer in patients. Additional patents are pending in Europe, Asia, and
South America.
"These approvals validate and enhance the value of our technology,"
states BioModa's Chief Technical Officer, Jeff Garwin, M.D., Ph.D.
"BioModa is a leader in developing integrated disease management for
lung cancer, with a coherent technology to diagnose, image, treat and
monitor patients with the disease."
The core technology was licensed in 1995 from the University of
California, through the Industrial Partnership Office of the Los Alamos
National Laboratory. The license is an exclusive, worldwide license.
"BioModa plans to file additional patent applications within the next 18
months, to enhance the market value of products in development," says
Dr. Garwin. |
